Kit, composition, and combination therapy for fragile x syndrome

Abstract

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

1 - 29 . (canceled) 
     
     
         30 . A method of treating fragile x syndrome by combination therapy in a subject in need thereof comprising administering to the subject simultaneously, separately or sequentially an effective amount of the combination of:
 sulindac, or a pharmaceutically acceptable salt thereof; and   (ii) ibudilast or a pharmaceutically acceptable salt thereof.   
     
     
         31 . The method of  claim 30 , wherein the subject exhibits signs of hyperactivity, social anxiety, memory loss, or disruptive behaviour. 
     
     
         32 . The method of  claim 30 , wherein the subject is human. 
     
     
         33 . The method of  claim 30 , wherein sulindac and ibudilast are administered simultaneously in a single dose once per day. 
     
     
         34 . The method of  claim 33 , wherein the single dose comprises 200 mg to 400 mg of sulindac. 
     
     
         35 . The method of  claim 30 , wherein sulindac and ibudilast are administered simultaneously in a single dose twice per day. 
     
     
         36 . The method of  claim 35 , wherein the single dose comprises 150 mg to 200 mg of sulindac. 
     
     
         37 . The method of  claim 30 , wherein sulindac and ibudilast are administered orally. 
     
     
         38 . The method of  claim 30 , wherein sulindac and ibudilast are administered parenterally, transdermally, sublingually, rectally or by inhalation. 
     
     
         39 . The method of  claim 30 , wherein the subject is human; and sulindac and ibudilast are administered simultaneously in a single dose once per day. 
     
     
         40 . The method of  claim 30 , wherein the subject is human; and sulindac and ibudilast are administered simultaneously in a single dose twice per day.